# Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients

> **NCT00166296** · PHASE2 · COMPLETED · sponsor: **Germans Trias i Pujol Hospital** · enrollment: 133 (actual)

## Conditions studied

- Major Depressive Disorder
- Hepatitis C, Chronic

## Interventions

- **DRUG:** Escitalopram
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00166296
- **Lead sponsor:** Germans Trias i Pujol Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 133 (ACTUAL)
- **Last updated:** 2020-08-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00166296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00166296, "Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00166296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*